The CANTOS trial assessed canakinumab, a monoclonal antibody interleukin-1β (IL-1β) antagonist, in patients with previous myocardial infarction and raised inflammatory markers and showed a small reduction in rates of myocardial infarction, accompanied by an increase in deaths attributable to infections (186). This evidence concerns the gene IL1B and myocardial infarction.